Skip to main content
Clinical Trials/NCT05427916
NCT05427916TerminatedNot Applicable

Prospective Randomized Evaluation of the Effect of Avance® Solo Negative Pressure Wound Therapy System or Optifoam® Gentle Post-Op Dressing on "High Risk" Closed Surgical Incisions; Freedom From Wound Complication Study

Icahn School of Medicine at Mount Sinai1 site in 1 country20 target enrollmentStarted: July 12, 2022Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Enrollment
20
Locations
1
Primary Endpoint
Number of Participants With Healing Complication

Study Overview

Brief Summary

The primary objective is to assess the frequency of a wound healing complication, in a closed incisional wound in a "high risk" surgical incision when treated with Negative Pressure Wound Therapy versus a highly absorbent antimicrobial post - operative absorbent dressing.

Detailed Description

A healing complication is defined as presence of at least one of the following conditions: infection (superficial or deep), dehiscence (partial, superficial, or deep), or delayed healing (incision not 100% closed within 7 days of the first surgical procedure), drainage form the wound after 96 hours post operatively.

The secondary objectives are to assess any changes in the following assessments of the surgical incision weekly over the treatment period:

  • Surrounding skin condition
  • Incision complications, infection or clinical signs of infection
  • to assess the number and type of these complications individually including other postsurgical complications: skin necrosis, cellulitis, abscess, suture abscess, seroma, periwound edema or hematoma occurring within 21, 42, and 90 days postoperatively
  • Pain during dressing changes

Assessment of the following at dressing changes:

  • Duration/wear time
  • Ease of use; difficulty with sleep
  • Damage to surrounding skin on removal
  • Assessment of re-epithelialization/closure
  • Patient comfort during wear; ease of ambulation
  • Conformability of dressing
  • Exudate management
  • Reasons for removal

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •The patient must be at least 18 years of age.
  • •Males and females - provided they are not pregnant and if of reproductive age are using contraception.
  • •Have a closed surgical incision post-surgery/closure (<24 hours after).
  • •The patient is able to understand the evaluation and is willing to consent to the evaluation.
  • •Undergoing appropriate: wound "high risk" surgery.
  • •Foot and ankle surgery.
  • •Vascular groin incision.
  • •Long leg vein harvest incision.
  • •Closed forefoot and major amputation surgery.
  • •Possibly: breast augmentation and reduction surgery.
  • •HIV and hepatitis positive patients will not be excluded from this study.
  • •Renal failure patients will not be excluded.
  • •Patient on metabolic agent, immunosuppressants, or steroid therapy will not be excluded from this study.

Exclusion Criteria

  • •Incisions in excess of effective dressing pad size provided.
  • •Patients with a known history of poor compliance with medical treatment.
  • •Patients who have participated in this trial previously and who were withdrawn.
  • •Patients with known allergies to product components (silicone adhesives and polyurethane films (direct contact with incision), acrylic adhesives (direct contact with skin), polyethylene fabrics and super-absorbent powders (polyacrylates) (within the dressing).
  • •Incisions where daily inspection is required underneath the dressing.
  • •Incisions which have an infection which is not being treated with systemic antibiotics.
  • •Incisions which are actively bleeding.
  • •Exposure of blood vessels, organs, bone or tendon at the base of the reference incision.

Arms & Interventions

Negative Pressure Wound Therapy

Experimental

Negative pressure to the incision site and managing exudate generated by the incision.

Intervention: Avance Solo (Device)

Optifoam

Active Comparator

This foam is standard of care and is currently stocked by the operating rooms at Mount Sinai hospital and indicated for use in high risk wounds

Intervention: Optifoam (Other)

Outcomes

Primary Outcomes

Number of Participants With Healing Complication

Time Frame: 21 days

Healing complications are defined as the presence of at least one of the following conditions: infection (superficial or deep), dehiscence (partial, superficial, or deep), or delayed healing (incision not 100% closed within 7 days of the first surgical procedure)

Secondary Outcomes

  • Number of Cellulitis Complications(90 days)
  • Number of Skin Necrosis Complications(90 days)
  • Number of Seroma Complications(90 days)
  • Pain During Dressing Changes(90 days)
  • Number of Abscess Complications(90 days)
  • Number of Hematoma Complications(90 days)
  • Number of Suture Abscess Complications(90 days)
  • Number of Periwound Edema Complications(90 days)
  • Patient Satisfaction(90 days)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

John Lantis

Professor

Icahn School of Medicine at Mount Sinai

Study Sites (1)

Loading locations...

Similar Trials